Linked from

The 36 pages that link to Pharmacovigilance, each with the reason it gives.

• Traditional medicineRelated: Monitoring harms matters when traditional products are used alongside other treatments.

• Adverse drug reactionNarrower topic: It gathers reports and evidence to identify risks that were missed before approval.

• PharmacologyRelated: Monitoring medicines after use reveals risks not fully captured before approval.

• Mass drug administrationRelated: Large campaigns need systems to detect and respond to adverse events across treated populations.

• Pharmaceutical industryRelated: Safety monitoring continues after products reach patients.

• Drug regulationRelated: Safety monitoring continues after approval, when much larger populations use a medicine.

• ThalidomideNarrower topic: Thalidomide demonstrated why safety monitoring must continue after a drug reaches market.

• NephrotoxicityNarrower topic: Reports of kidney injury help identify medication risks after drugs reach wider use.

• Public health surveillanceCompared with: It monitors medicine safety, a narrower focus than population-wide health surveillance.

• PharmacyRelated: Pharmacists help identify and report safety problems after medicines reach patients.

• PharmacognosyRelated: Monitoring adverse effects is essential when natural products enter widespread clinical use.

• TeratogenicityRelated: Post-market monitoring can uncover pregnancy risks missed before approval.

• Herb–drug interactionNarrower topic: Reports of suspected supplement interactions contribute to evidence about uncommon or poorly studied harms.

• Over-the-counter drugNarrower topic: Reports of harms from OTC use help regulators identify risks after products reach the market.

• ContraindicationRelated: Safety reports can reveal harms that lead to new contraindications or revised guidance.

• AkathisiaNarrower topic: Better detection of medication-related akathisia depends on reporting and evaluating adverse drug reactions.

• Drug developmentRelated: Safety monitoring continues after approval, when broader populations use the medicine.

• European Medicines AgencyNarrower topic: The agency coordinates safety monitoring throughout a medicine's marketed life.

• Merck & Co.Related: Post-approval safety monitoring continues after Merck products reach patients.

• PharmacotherapyRelated: Safety surveillance identifies harms that may not be evident before widespread use.

• Prescription drugRelated: Safety reports after dispensing help identify harms not apparent before authorization.

• Case reportRelated: Case reports can provide early signals that warrant formal safety investigation.

• Adverse eventNarrower topic: Adverse-event reports are a central source of safety information for this broader discipline.

• ACE inhibitor coughRelated: Reports of cough help characterize its frequency and distinguish it from other respiratory symptoms.

• Bristol Myers SquibbRelated: Safety monitoring continues after approval as medicines reach larger patient populations.

• Clinical pharmacologyRelated: It monitors harms that may emerge after broader use than clinical trials can provide.

• MetamizoleNarrower topic: Monitoring reports of blood disorders has influenced decisions about metamizole’s safety.

• MontelukastNarrower topic: Postmarketing safety reports helped identify concerns not fully captured before approval.

• PharmacistRelated: Pharmacists report and investigate suspected medicine-related harms.

• ThiomersalNarrower topic: Monitoring systems evaluate suspected harms associated with vaccines and their ingredients.

• African traditional medicineRelated: Monitoring can identify harms linked to traditional preparations and their use.

• Drug classRelated: Safety monitoring can identify risks shared across a drug class after widespread use.

• History of pharmacyRelated: Post-market safety monitoring emerged as a response to harms from widely used medicines.

• SalmeterolNarrower topic: Post-marketing safety monitoring helped identify risks associated with LABA treatment.

• Toxic epidermal necrolysisRelated: Reporting suspected cases helps identify dangerous medication associations.

• Medicine (drug or remedy)Related: Monitoring after use can reveal risks missed before approval.